Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Coagulation

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

EDTA: Chemistry and Properties

EDTA: Chemistry and Properties

Polydentate ligands are most widely used in complexometric titrations because they form more stable complexes with the metal ions than mono- or bidentate ligands due to the chelate effect. Examples of polydentate ligands are ethylenediaminetetraacetic acid (EDTA), crown ethers, and cryptands. The most important feature of optimal polydentate ligands is the ability to form 1:1 complexes in a single-step process. Amino carboxylic acid derivatives are frequently used as complexing agents. EDTA is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lipid specificity of the membrane binding domain of coagulation factor X.

Journal of thrombosis and haemostasis : JTH·2017

Same author

Polyphosphate as modulator of hemostasis, thrombosis, and inflammation.

Journal of thrombosis and haemostasis : JTH·2015

Same author

Polyphosphate, platelets, and coagulation.

International journal of laboratory hematology·2015

Same author

Factor XI anion-binding sites are required for productive interactions with polyphosphate.

Journal of thrombosis and haemostasis : JTH·2013

Same author

Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.

Journal of thrombosis and haemostasis : JTH·2013

Same author

Polyphosphate multi-tasks.

Journal of thrombosis and haemostasis : JTH·2012

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Assaying for Inorganic Polyphosphate in Bacteria

Assaying for Inorganic Polyphosphate in Bacteria

Published on: January 21, 2019

Polyphosphate as a general procoagulant agent.

S A Smith¹, J H Morrissey

¹Department of Internal Medicine, College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. sasmith6@uiuc.edu

Journal of Thrombosis and Haemostasis : JTH

|July 31, 2008

Summary

This summary is machine-generated.

Polyphosphate, released by platelets, accelerates blood clotting. This study shows polyphosphate can reverse anticoagulant effects and aid bleeding treatment in hemophilia patients.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jul 3, 2026

Assaying for Inorganic Polyphosphate in Bacteria

Assaying for Inorganic Polyphosphate in Bacteria

Published on: January 21, 2019

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Area of Science:

Biochemistry
Hematology
Hemostasis

Background:

Polyphosphate is secreted by activated platelets.
Polyphosphate accelerates blood clotting by triggering the contact pathway and promoting Factor V activation.

Purpose of the Study:

To investigate the procoagulant effects of polyphosphate in hemophilia and in the presence of anticoagulants.
To determine if polyphosphate can reverse the effects of anticoagulant drugs.

Main Methods:

Assessed polyphosphate's effect on clotting time in hemophilia A and B plasmas.
Evaluated polyphosphate's impact on clotting dynamics in whole blood with various anticoagulants using thromboelastography.
Investigated polyphosphate's mechanism of action by studying its effect on Factor V activation.

Main Results:

Polyphosphate significantly shortened clotting times in hemophilia A and B plasmas.
Polyphosphate reversed the anticoagulant effects of heparin, enoxaparin, argatroban, and rivaroxaban, normalizing clotting dynamics.
Polyphosphate antagonizes anticoagulant effects by accelerating Factor V activation.

Conclusions:

Polyphosphate demonstrates potential for reversing anticoagulation.
Polyphosphate may be beneficial in treating bleeding episodes in hemophilia patients.